Onconetix, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.1K | $21.5K | $303.6K | $303.7K | $106.5K | $101.6K | $712.0K | $406.9K |
| Cost of Revenue | $12.8K | $23.1K | $55.9K | $34.8K | $36.0K | $55.8K | $52.0K | $301.4K |
| Gross Profit | $4.3K | $-1.7K | $247.7K | $268.9K | $70.5K | $45.8K | $660.0K | $105.4K |
| Gross Margin | 25.1% | -7.7% | 81.6% | 88.6% | 66.2% | 45.1% | 92.7% | 25.9% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | $24.5K | — | $109.4K |
| SG&A Expense | $2.2M | $2.0M | $1.5M | $2.3M | $1.5M | $1.7M | $2.6M | $2.6M |
| Operating Income | $-2.7M | $-10.2M | $-1.3M | $-2.1M | $-1.9M | $-12.6M | $-29.1M | $-2.6M |
| Operating Margin | -15,950.9% | -47,657.2% | -422.1% | -681.5% | -1,817.4% | -12,369.2% | -4,093.7% | -650.3% |
| Interest Expense | — | $2.0K | — | — | $200.0K | $200.0K | — | $153.3K |
| Pretax Income | $-2.9M | $-4.2M | $5.7M | $-8.8M | $-2.4M | $-8.5M | $-30.4M | $-3.9M |
| Income Tax Expense | — | — | — | — | — | — | $-918.0K | $-56.4K |
| Net Income | $-2.9M | $-4.2M | $5.7M | $-8.8M | $-2.4M | $-8.5M | $-29.4M | $-3.8M |
| Net Margin | -16,748.3% | -19,643.4% | 1,867.5% | -2,892.7% | -2,227.8% | -8,408.8% | -4,134.7% | -940.7% |
| EPS (Basic) | $-1.28 | $-6.71 | $454.85 | $-0.22 | $-8.20 | $-7.84 | $21.98 | $-8.59 |
| EPS (Diluted) | $-1.28 | $-6.71 | $454.85 | $-0.22 | $-8.20 | $-7.84 | $21.98 | $-8.59 |
| Shares Outstanding (Basic) | 2.2M | 628.5K | 937.7K | 40.8M | 329.2K | 527.1M | 4.0M | 241.1M |
| Shares Outstanding (Diluted) | 2.2M | 628.5K | 937.7K | 40.8M | 329.2K | 527.1M | 4.0M | 241.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |